Genetic Testing in Oncology: 5 Things Payers Should Know
With cancer, the idea that genetic information can be used to shape personalised care has captivated the public’s imagination, which is why payers face intense pressure from employers, laboratories, and members to cover every promising new genomic test on the market.
However, just because a test doesn’t exist, doesn’t mean that we fully understand the best way to apply it. In a rapidly expanding field such as genomics, the ability to use it to improve patient outcomes, or even to accurately interpret the results gets outpaced by technology.
As genomics continue to evolve, Modern Medicine Network has pointed out five things to know about genetic testing and counselling to ensure that payers, patients and providers are getting the most out of these exciting technologies and the care they can inform.
- A fair amount of tumour testing goes well beyond the current evidence for it.
- Tumour profiling test results may point to underlying BRCA or other inherited mutations that should be addressed.
- Liquid biopsy technology is exciting – but is it ready for prime time?
- There’s a lot of buzz, but little evidence to date, for emerging multi-omics tests.
- Payers can play a pivotal role in advancing personalised medicine.
Find this interesting? You should head over to Modern Medicine Network where Rebecca Sutphen, MD, FACMG, President and Chief Medical Officer at InformedDNA explains each point above in detail.